Tags

Type your tag names separated by a space and hit enter

Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency.
J Med Assoc Thai. 2010 Aug; 93(8):885-91.JM

Abstract

OBJECTIVE

To evaluate 25 hydroxyvitamin D (25-OH-D) deficiency in a cohort ofpredialysis CKD patients and the treatment effect and safety of high dose ergocalciferol supplement in predialysis CKD.

MATERIAL AND METHOD

Fifty-six predialysis CKD patients who came for a regular visit at a single hospital with calculated glomerular filtration rate < or =60 mL/min/1.73 m2 were screened for 25-OH-D levels. Forty-four patients with 25-OH-D deficiency were recruited into this prospective observational study that examined the effect of high dose oral ergocalciferol supplementation. After eight weeks, 37 patients completed the follow-up and biochemical parameters were reevaluated and analyzed.

RESULTS

The mean 25-OH-D level of 56 patients was 25.6 +/- 8 ng/mL. Forty-four (78.5%) patients had 25-OH-D levels less than 30 ng/mL and four (7.1%) had severe deficiency with the level less than 15 ng/mL. High dose ergocalciferol supplement successively increased 25-OH-D levels in 35 (95%) patients. 25-OH-D levels increased significantly from 22 +/- 4.8 to 34.5 +/- 10.8 ng/mL after eight weeks (p < 0.001). During the study period, there were no changes in serum calcium, phosphate, and PTH. There was no other side effect associated with the treatment.

CONCLUSION

25-OH-D deficiency were found in this cohort of predialysis CKD patients. Ergocalciferol was a safe and effective supplement for the 25-OH-D in predialysis CKD.

Authors+Show Affiliations

Division of Nephrology, Department ofMedicine, BMA Medical college and Vajira Hospital, Bangkok, Thailand. thananda@hotmail.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20718162

Citation

Trakarnvanich, Thananda, et al. "Effect of High Dose Ergocalciferol in Chronic Kidney Disease Patients With 25-hydroxyvitamin D Deficiency." Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, vol. 93, no. 8, 2010, pp. 885-91.
Trakarnvanich T, Chalapipat O, Disthabanchong S, et al. Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency. J Med Assoc Thai. 2010;93(8):885-91.
Trakarnvanich, T., Chalapipat, O., Disthabanchong, S., Kurathong, S., Praditpornsilpa, K., Stitchantrakul, W., & Chailurkit, L. O. (2010). Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency. Journal of the Medical Association of Thailand = Chotmaihet Thangphaet, 93(8), 885-91.
Trakarnvanich T, et al. Effect of High Dose Ergocalciferol in Chronic Kidney Disease Patients With 25-hydroxyvitamin D Deficiency. J Med Assoc Thai. 2010;93(8):885-91. PubMed PMID: 20718162.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effect of high dose ergocalciferol in chronic kidney disease patients with 25-hydroxyvitamin D deficiency. AU - Trakarnvanich,Thananda, AU - Chalapipat,Oran, AU - Disthabanchong,Sinee, AU - Kurathong,Sathit, AU - Praditpornsilpa,Kearkiat, AU - Stitchantrakul,Wasana, AU - Chailurkit,La-Or, PY - 2010/8/20/entrez PY - 2010/8/20/pubmed PY - 2010/9/10/medline SP - 885 EP - 91 JF - Journal of the Medical Association of Thailand = Chotmaihet thangphaet JO - J Med Assoc Thai VL - 93 IS - 8 N2 - OBJECTIVE: To evaluate 25 hydroxyvitamin D (25-OH-D) deficiency in a cohort ofpredialysis CKD patients and the treatment effect and safety of high dose ergocalciferol supplement in predialysis CKD. MATERIAL AND METHOD: Fifty-six predialysis CKD patients who came for a regular visit at a single hospital with calculated glomerular filtration rate < or =60 mL/min/1.73 m2 were screened for 25-OH-D levels. Forty-four patients with 25-OH-D deficiency were recruited into this prospective observational study that examined the effect of high dose oral ergocalciferol supplementation. After eight weeks, 37 patients completed the follow-up and biochemical parameters were reevaluated and analyzed. RESULTS: The mean 25-OH-D level of 56 patients was 25.6 +/- 8 ng/mL. Forty-four (78.5%) patients had 25-OH-D levels less than 30 ng/mL and four (7.1%) had severe deficiency with the level less than 15 ng/mL. High dose ergocalciferol supplement successively increased 25-OH-D levels in 35 (95%) patients. 25-OH-D levels increased significantly from 22 +/- 4.8 to 34.5 +/- 10.8 ng/mL after eight weeks (p < 0.001). During the study period, there were no changes in serum calcium, phosphate, and PTH. There was no other side effect associated with the treatment. CONCLUSION: 25-OH-D deficiency were found in this cohort of predialysis CKD patients. Ergocalciferol was a safe and effective supplement for the 25-OH-D in predialysis CKD. SN - 0125-2208 UR - https://www.unboundmedicine.com/medline/citation/20718162/Effect_of_high_dose_ergocalciferol_in_chronic_kidney_disease_patients_with_25_hydroxyvitamin_D_deficiency_ L2 - http://www.diseaseinfosearch.org/result/3996 DB - PRIME DP - Unbound Medicine ER -